BioNTech Finalizes Acquisition of InstaDeep for $549M
by 
BioNTech has officially completed the acquisition of InstaDeep Ltd.—a technology company in the artificial intelligence (AI) and machine learning (ML) space— for approximately $549 million. The takeover follows a collaboration between the two parties since 2019 and an equity investment by BioNTech in InstaDeep through a Series B funding round held in January 2022.
BioNTech expects that the deal will help it establish robust expertise in AI-powered drug discovery and the development of advanced vaccines and immunotherapies for conditions with high unmet medical needs. InstaDeep will serve as BioNTech’s global subsidiary in the UK.
The acquisition supports BioNTech’s strategy of aiming to build capabilities in AI-driven drug discovery and development of immunotherapies and vaccines to address diseases with high unmet medical need. InstaDeep will operate as a UK-based global subsidiary of BioNTech. InstaDeep will continue to offer services to global customers in fields including technology, transport and logistics, and industrial and financial services.
This deal will also support BioNTech in bolstering its worldwide research partners’ network in the sector and growing its footprint in talent hubs in the Middle East, the US, Europe and Africa.
For our upcoming conference visit – https://virtueinsight.com/upcoming-conferences/